Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATRA NASDAQ:LXEO NASDAQ:ORIC NASDAQ:STTK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATRAAtara Biotherapeutics$10.46+6.1%$7.48$3.92▼$19.15$88.84M0.11135,406 shs42,826 shsLXEOLexeo Therapeutics$4.20+1.7%$5.54$3.60▼$10.99$324.29M1.38654,308 shs591,142 shsORICOric Pharmaceuticals$7.82+3.7%$9.01$7.23▼$14.93$780.52M1.041.67 million shs2.17 million shsSTTKShattuck Labs$4.18+1.2%$6.38$0.71▼$8.33$316.69M1.08918,465 shs927,199 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATRAAtara Biotherapeutics+0.92%+2.39%+12.30%+42.90%+8.11%LXEOLexeo Therapeutics-2.59%-8.22%-32.52%-37.71%-10.41%ORICOric Pharmaceuticals-5.75%-3.83%-16.13%-35.88%-22.67%STTKShattuck Labs-3.28%-13.05%-41.17%-32.63%+256.03%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATRAAtara Biotherapeutics$10.46+6.1%$7.48$3.92▼$19.15$88.84M0.11135,406 shs42,826 shsLXEOLexeo Therapeutics$4.20+1.7%$5.54$3.60▼$10.99$324.29M1.38654,308 shs591,142 shsORICOric Pharmaceuticals$7.82+3.7%$9.01$7.23▼$14.93$780.52M1.041.67 million shs2.17 million shsSTTKShattuck Labs$4.18+1.2%$6.38$0.71▼$8.33$316.69M1.08918,465 shs927,199 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATRAAtara Biotherapeutics+0.92%+2.39%+12.30%+42.90%+8.11%LXEOLexeo Therapeutics-2.59%-8.22%-32.52%-37.71%-10.41%ORICOric Pharmaceuticals-5.75%-3.83%-16.13%-35.88%-22.67%STTKShattuck Labs-3.28%-13.05%-41.17%-32.63%+256.03%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATRAAtara Biotherapeutics 2.00Hold$9.50-9.18% DownsideLXEOLexeo Therapeutics 2.88Moderate Buy$20.14379.59% UpsideORICOric Pharmaceuticals 2.75Moderate Buy$19.36147.62% UpsideSTTKShattuck Labs 2.80Moderate Buy$11.00163.16% UpsideCurrent Analyst Ratings BreakdownLatest ATRA, ORIC, STTK, and LXEO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/8/2026ORICOric Pharmaceuticals BenchmarkSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/8/2026ORICOric Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.006/8/2026STTKShattuck Labs Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$14.00 ➝ $17.006/8/2026STTKShattuck Labs HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$18.006/5/2026STTKShattuck Labs Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeOutperform$7.006/5/2026STTKShattuck Labs CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy$7.006/2/2026STTKShattuck Labs Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/29/2026LXEOLexeo Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/22/2026ORICOric Pharmaceuticals Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight5/19/2026STTKShattuck Labs Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/18/2026ATRAAtara Biotherapeutics Freedom CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold(Data available from 6/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATRAAtara Biotherapeutics$120.77M0.78$5.20 per share2.01($5.34) per share-1.96LXEOLexeo TherapeuticsN/AN/AN/AN/A$3.38 per shareN/AORICOric PharmaceuticalsN/AN/AN/AN/A$3.90 per shareN/ASTTKShattuck Labs$1M320.53N/AN/A$1.30 per share3.22Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATRAAtara Biotherapeutics$32.69M-$0.67N/A52.30N/A-40.91%-79.12%-35.29%8/10/2026 (Estimated)LXEOLexeo Therapeutics-$99.96M-$1.45N/AN/AN/AN/A-47.48%-41.72%8/13/2026 (Estimated)ORICOric Pharmaceuticals-$129.47M-$1.44N/AN/AN/AN/A-35.33%-33.31%8/11/2026 (Estimated)STTKShattuck Labs-$48.81M-$0.63N/AN/AN/AN/A-60.73%-55.75%8/13/2026 (Estimated)Latest ATRA, ORIC, STTK, and LXEO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026ATRAAtara Biotherapeutics-$0.3295-$0.29+$0.0395-$0.29$2.90 million$0.52 million5/11/2026Q1 2026LXEOLexeo Therapeutics-$0.29-$0.25+$0.04-$0.25N/AN/A5/7/2026Q1 2026STTKShattuck Labs-$0.14-$0.13+$0.01-$0.13N/AN/A5/4/2026Q1 2026ORICOric Pharmaceuticals-$0.31-$0.34-$0.03-$0.34N/AN/A3/30/2026Q4 2025LXEOLexeo Therapeutics-$0.32-$0.27+$0.05-$0.27N/AN/A3/16/2026Q4 2025ATRAAtara Biotherapeutics-$0.68-$0.25+$0.43-$0.36$0.70 million$1.60 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthATRAAtara BiotherapeuticsN/AN/AN/AN/AN/ALXEOLexeo TherapeuticsN/AN/AN/AN/AN/AORICOric PharmaceuticalsN/AN/AN/AN/AN/ASTTKShattuck LabsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATRAAtara BiotherapeuticsN/A2.162.16LXEOLexeo TherapeuticsN/A14.1614.16ORICOric PharmaceuticalsN/A16.3316.33STTKShattuck LabsN/A22.0722.06Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATRAAtara Biotherapeutics70.90%LXEOLexeo Therapeutics60.67%ORICOric Pharmaceuticals95.05%STTKShattuck Labs58.74%Insider OwnershipCompanyInsider OwnershipATRAAtara Biotherapeutics41.20%LXEOLexeo Therapeutics5.30%ORICOric Pharmaceuticals5.70%STTKShattuck Labs8.79%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATRAAtara Biotherapeutics3309.01 million5.30 millionNo DataLXEOLexeo Therapeutics5878.52 million74.36 millionNot OptionableORICOric Pharmaceuticals80103.52 million97.62 millionOptionableSTTKShattuck Labs10076.68 million69.94 millionOptionableATRA, ORIC, STTK, and LXEO HeadlinesRecent News About These CompaniesShattuck Labs Prices Upsized Public Equity and Warrant OfferingJune 11 at 8:50 AM | tipranks.comShattuck Labs: "Hold" On Phase 1 SL-325 Data And Next Stage Of DevelopmentJune 10 at 11:21 PM | seekingalpha.comShattuck Labs drops 6%, prices $75M share raise at $4 per shareJune 10 at 11:21 PM | msn.comWhat's going on with Shattuck Labs stock Wednesday?June 10 at 11:21 PM | msn.comShattuck Labs, Inc. Announces Pricing of $75 Million Public OfferingJune 9 at 12:21 AM | globenewswire.comH.C. Wainwright Sticks to Its Buy Rating for Shattuck Labs (STTK)June 9 at 10:17 PM | theglobeandmail.comShattuck Labs launches proposed public offering of common stockJune 9 at 5:17 PM | msn.comShattuck Labs, Inc. Announces Public Offering of Common Stock and Pre-Funded WarrantsJune 9 at 4:31 PM | quiverquant.comQShattuck Labs, Inc. Announces Proposed Public OfferingJune 9 at 4:18 PM | globenewswire.comShattuck Labs Announces Exercise of Outstanding Common Stock Warrants and Provides Financial UpdateJune 9 at 8:00 AM | globenewswire.comShattuck Labs, Inc. (STTK) Discusses Phase I Results for DR3 Blocking Antibody SL-325 and Pipeline Update TranscriptJune 8 at 2:01 PM | seekingalpha.comWhy Is Shattuck Labs Stock Trading Lower On Monday?June 8 at 1:00 PM | benzinga.comShattuck Labs Reports Promising Phase 1 Results for SL-325, a Potential First-in-Class DR3 Blocking Antibody for Crohn's DiseaseJune 8 at 6:31 AM | quiverquant.comQShattuck Labs Announces Phase 1 Results for SL-325June 8 at 6:00 AM | globenewswire.comShattuck Labs Shareholders Approve Directors, Compensation, Governance MeasuresJune 6, 2026 | theglobeandmail.comShattuck Labs to Present Phase 1 Clinical Data for SL-325 and Pipeline Update on June 8, 2026June 5, 2026 | quiverquant.comQShattuck Labs to Host Investor Call and Webcast on Phase 1 Clinical Data of SL-325, a Potentially First-in-Class DR3 Blocking Antibody, and Pipeline Update on June 8June 5, 2026 | markets.businessinsider.comShattuck Labs to Host Investor Call and Webcast on Phase 1 Clinical Data of SL-325, a Potentially First-in-Class DR3 Blocking Antibody, and Pipeline Update on June 8June 5, 2026 | globenewswire.comShattuck Labs: Priced As If Risk Was Not A Part Of The EquationMay 22, 2026 | seekingalpha.comShattuck Labs (NASDAQ:STTK) Insider Sells $14,244.32 in StockMay 15, 2026 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSpaceX IPO: Opportunity? Or the Ultimate Hype Trade?By Chris Markoch | May 22, 2026The Great SPR Arbitrage: An Oil Market Glitch Fuels Sector GainsBy Jeffrey Neal Johnson | May 14, 2026Datadog Soars, Dynatrace Slumps: Gap Widens in AI Agent StocksBy Leo Miller | May 18, 2026From Runway to Riches: Victoria's Secret's New LookBy Jeffrey Neal Johnson | June 4, 2026The Great AI Rotation: Cashing In on DataBy Jeffrey Neal Johnson | May 20, 2026ATRA, ORIC, STTK, and LXEO Company DescriptionsAtara Biotherapeutics NASDAQ:ATRA$10.46 +0.60 (+6.09%) As of 04:00 PM EasternAtara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.Lexeo Therapeutics NASDAQ:LXEO$4.20 +0.07 (+1.69%) Closing price 04:00 PM EasternExtended Trading$4.30 +0.10 (+2.48%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.Oric Pharmaceuticals NASDAQ:ORIC$7.82 +0.28 (+3.71%) Closing price 04:00 PM EasternExtended Trading$8.05 +0.23 (+2.94%) As of 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.Shattuck Labs NASDAQ:STTK$4.18 +0.05 (+1.21%) Closing price 04:00 PM EasternExtended Trading$4.41 +0.23 (+5.50%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Spotify's "North Star" Outlook Was Music to Investors Ears DraftKings Hits the Jackpot With Super App Pivot Cracker Barrel Surges 23% as Earnings Beat Signals Turnaround Progress Microsoft Just Gave Investors 3 Dates They Can't Afford to Ignore SpaceX IPO Fears Are Overblown, But the AI Bet Is Real The Biggest Opportunity From SpaceX’s IPO May Surprise You NVIDIA’s Outlook Gains Momentum: Stock Price to Follow Chewy’s Growth Engine Is Stronger Than the Market Thinks Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
